WCG Wealth Advisors LLC Invests $1.37 Million in Boston Scientific Corporation $BSX

WCG Wealth Advisors LLC acquired a new position in shares of Boston Scientific Corporation (NYSE:BSX) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 14,402 shares of the medical equipment provider’s stock, valued at approximately $1,373,000.

Several other large investors have also added to or reduced their stakes in BSX. Murphy & Mullick Capital Management Corp boosted its holdings in Boston Scientific by 200.0% during the third quarter. Murphy & Mullick Capital Management Corp now owns 255 shares of the medical equipment provider’s stock worth $25,000 after purchasing an additional 170 shares during the last quarter. FWL Investment Management LLC acquired a new position in Boston Scientific during the second quarter worth $26,000. Colonial Trust Co SC lifted its stake in Boston Scientific by 502.2% in the third quarter. Colonial Trust Co SC now owns 277 shares of the medical equipment provider’s stock valued at $27,000 after acquiring an additional 231 shares during the last quarter. Bangor Savings Bank lifted its stake in Boston Scientific by 94.7% in the fourth quarter. Bangor Savings Bank now owns 292 shares of the medical equipment provider’s stock valued at $28,000 after acquiring an additional 142 shares during the last quarter. Finally, Board of the Pension Protection Fund acquired a new stake in Boston Scientific in the fourth quarter valued at $29,000. Institutional investors and hedge funds own 89.07% of the company’s stock.

More Boston Scientific News

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Canaccord reiterated a Buy rating on Boston Scientific, even though it trimmed its price target slightly to $70 from $71, signaling continued confidence in the company’s long-term outlook. Is Boston Scientific Corporation (BSX) One of the Top Cheap Stocks With Strong Buy Ratings on Wall Street?
• Positive Sentiment: Truist also kept a Buy rating, though it cut its price target to $64 from $85, suggesting analysts still see meaningful upside despite a more cautious valuation view. Benzinga
• Positive Sentiment: The company announced plans for a $138 million medical device distribution facility in Indiana, which should expand operations and add 300 jobs, a sign of ongoing investment in growth and logistics capacity. Boston Scientific to open $138M medical device distribution facility in Indiana, adding 300 jobs
• Neutral Sentiment: Boston Scientific’s last reported quarter was strong, with revenue of $5.20 billion and EPS of $0.80 beating expectations, but the company also cut guidance due to stronger competition in cardiac devices and slower Watchman growth, creating a mixed fundamental backdrop. How Investors May Respond To Boston Scientific (BSX) Strong Q1 Beat But Cut Guidance On Watchman Growth
• Neutral Sentiment: Recent market commentary noted BSX has been trading above market averages on some sessions, but also lagging some peers, reflecting choppy investor sentiment rather than a clear trend. Boston Scientific Corp. stock underperforms Thursday when compared to competitors despite daily gains
• Negative Sentiment: The repeated reductions in price targets from analysts, including Truist and Canaccord, suggest expectations have reset lower, which can weigh on sentiment even when ratings remain positive. Is Boston Scientific Corporation (BSX) One of the Top Cheap Stocks With Strong Buy Ratings on Wall Street?

Insider Buying and Selling at Boston Scientific

In related news, Director Edward J. Ludwig purchased 3,580 shares of Boston Scientific stock in a transaction dated Wednesday, May 20th. The shares were bought at an average cost of $56.68 per share, for a total transaction of $202,914.40. Following the purchase, the director owned 25,359 shares in the company, valued at approximately $1,437,348.12. This trade represents a 16.44% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director David C. Habiger purchased 2,250 shares of Boston Scientific stock in a transaction dated Wednesday, May 20th. The stock was bought at an average price of $55.92 per share, for a total transaction of $125,820.00. Following the completion of the purchase, the director owned 13,878 shares in the company, valued at $776,057.76. This represents a 19.35% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have bought a total of 9,800 shares of company stock valued at $554,012 in the last ninety days. 0.34% of the stock is currently owned by company insiders.

Boston Scientific Price Performance

NYSE:BSX opened at $48.66 on Friday. Boston Scientific Corporation has a 52 week low of $47.17 and a 52 week high of $109.50. The firm has a market cap of $72.32 billion, a price-to-earnings ratio of 20.36, a P/E/G ratio of 0.91 and a beta of 0.56. The firm’s 50-day simple moving average is $58.11 and its 200 day simple moving average is $76.70. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.22 and a current ratio of 1.90.

Boston Scientific (NYSE:BSX) last released its earnings results on Wednesday, April 22nd. The medical equipment provider reported $0.80 EPS for the quarter, beating the consensus estimate of $0.79 by $0.01. Boston Scientific had a net margin of 17.29% and a return on equity of 19.17%. The firm had revenue of $5.20 billion for the quarter, compared to analyst estimates of $5.19 billion. During the same period last year, the firm earned $0.75 EPS. The business’s quarterly revenue was up 11.6% compared to the same quarter last year. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. As a group, sell-side analysts predict that Boston Scientific Corporation will post 3.37 earnings per share for the current year.

Boston Scientific announced that its board has authorized a share repurchase plan on Monday, May 18th that authorizes the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization authorizes the medical equipment provider to repurchase up to 6.4% of its stock through open market purchases. Stock repurchase plans are often an indication that the company’s management believes its stock is undervalued.

Wall Street Analyst Weigh In

A number of brokerages have commented on BSX. Canaccord Genuity Group cut their price target on shares of Boston Scientific from $71.00 to $70.00 and set a “buy” rating for the company in a research note on Monday. Wall Street Zen lowered shares of Boston Scientific from a “buy” rating to a “hold” rating in a research report on Saturday, March 28th. Truist Financial dropped their price objective on shares of Boston Scientific from $85.00 to $64.00 and set a “buy” rating on the stock in a research report on Thursday. Stifel Nicolaus set a $75.00 price objective on shares of Boston Scientific in a research report on Wednesday, May 27th. Finally, Royal Bank Of Canada reissued an “outperform” rating on shares of Boston Scientific in a research report on Thursday, May 28th. One analyst has rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and five have assigned a Hold rating to the company. Based on data from MarketBeat, Boston Scientific currently has a consensus rating of “Moderate Buy” and an average target price of $85.92.

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.